Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis

1John Foley, 2Gilles Defer, 3Lana Zhovtis Ryerson, 4Jeffrey A. Cohen, 5Douglas L. Arnold, 6Helmut Butzkueven, 7Gary Cutter, 8Gavin Giovannoni, 9Joep Killestein, 10Heinz Wiendl, 11Karen Smirnakis,11Shan Xiao,11George Kong,12Robert Kuhelj,11Nolan Campbell 1Rocky Mountain MS Clinic, Salt Lake City, United States; 2Department of Neurology, Centre Hospitalier Universitaire de Caen, Caen, France; 3Department of Neurology, NYU Langone Health, New…

Comparison of Time to Clinically Meaningful Improvement in Neuro-QOL in Patients Treated with Natalizumab Versus Ocrelizumab

1Carrie M. Hersh, 2Carl De Moor, 3Deborah M. Miller, 2Robin Avila, 2James R. Williams, 4Kathryn C. Fitzgerald, 2Menglan Pang, 3Marisa P. Mcginley, 5Megan Hyland, 6Tjalf Ziemssen, 7Irene Koulinska 1Mellen Program for MS, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, United States; 2Biogen, Cambridge, United States; 3Mellen Center, Cleveland Clinic, Cleveland, United States;…

Vitamin D3 Improves Behavioral Dysfunction and Promotes Remyelination in Multiple Sclerosis Model Induced by Cuprizone

1,2Kholoud M. Al-Otaibi, 3,4Badrah S Alghamdi, 1Maryam A. Al-Ghamdi, 1Ulfat Omar 1Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia; 2Department of Chemistry, Faculty of Science, Al-Baha University, Al-Baha, Saudi Arabia; 3Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 4Pre-Clinical Research Unit, King Fahd Medical Research…

Improvements in Quality of Life at 1 Year in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: An Interim Analysis of Clarify-MS

1Alessandra Solari, 2Xavier Montalban, 3,4Jeannette Lechner-Scott, 5Fredrik Piehl, 6Bruno Brochet, 7Dawn Langdon, 8Raymond Hupperts, 9Krzysztof Selmaj, 10Eva K. Havrdova, 11Francesco Patti, 12Luis Brieva, 13Eva Maria Maida, 14Nektaria Alexandri, 14Paul Kamudoni, 14Axel Nolting, 14Birgit Keller 1Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2Department of Neurology-Neuroimmunology Centre of Multiple Sclerosis of Catalonia (Cemcat), University Hospital…

Multiple Sclerosis Specialized Nurses in Saudi Arabia: Challenge, and Opportunities

1Rola Alarieh, 2Aida Balegh, 3Arij Khan, 4Asmaa Mejally, 5Fatima Almaghrabi, 6Joelle Massouh, 7Omar Saleh, 8Ouhoud Nazmi, 9Qamar Bukhari, 10Richel Sulague, 11Sawsan Almaymani, 12Waad Alsaggaf, 13Ahmed El Boghdady 1King Fahad Medical City, Riyadh, Saudi Arabia; 2King Abdulaziz Hospital (KAH), Al Mahiar, Jeddah, Saudi Arabia; 3King Fahad General Hospital (KFGH), Jeddah, Saudi Arabia; 4King Fahad National Guard Hospital (KFNGH), Riyadh, Saudi Arabia; 5Heraa Hospital, Makkah, Saudi Arabia; 6Nehme and Therese Tohme Multiple Sclerosis…

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets

1,2Bassem I Yamout, 3Peter Rieckmann, 4Diego Centonze, 5Gavin Giovannoni, 6Le H. Hua, 7,8Celia Oreja-Guevara, 9Daniel Selchen, 10Per Soelberg Sørensen, 11Patrick Vermersch, 12Heinz Wiendl, 13Hashem Salloukh 1Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut, Beirut, Lebanon; 2Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE; 3Center for Clinical Neuroplasticity, Medical Park Loipl, Bischofswiesen,…

Clinical Characteristics of Switching Between Disease Modifying Drugs Among a Sample of Egyptian Multiple Sclerosis Patients

1Asmaa Eissa, 2Tarek Menecie, 3Hoda Massoud, 2Mohammad Abboud, 2Mohammad H. Rashad 1Nasser institute hospital for research and treatment, Cairo, Egypt; 2Alazhar University, Cairo branch, Egypt; 3Alazhar university (for girls), Cairo branch, Egypt Introduction: Early and appropriate treatment decision for multiple sclerosis (MS) can markedly reduce disease activity and accumulation of disability to avoid many of…

Real-World Experience with Cladribine in the MSBase Registry

1Helmut Butzkueven, 2Tim Spelman, 3Suzanne Hodgkinson, 4Sara Eichau Madueño, 4Guillermo Izquierdo, 5Katherine Buzzard, 5Olga Skibina, 1Anneke Van Der Walt, 6Tomas Kalincik, 7François Grand-Maison 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia; 2MSBase Foundation, Alfred Centre, 99 Commercial Road, Melbourne, Australia; 3Liverpool Hospital, Sydney, Australia; 4Universitary Hospital Virgen Macarena, Seville, Spain; 5Box Hill Hospital,…

Anti-Inflammatory Compounds Ameliorate Locomotion and Anxiety Behaviors in Cuprizone Mouse Model of Multiple Sclerosis

1Rasha Mohammed Alderbi, 1Gadah Ali Alshahrany, 1Kholoud Ahmed Alyami, 1Hadeil Muhanna Alsufiani, 1Ulfat Mohammed Omar, 1Maryam A. Al-Ghamdi, 1Mohammad Z. Alam 1Department of biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia Introduction: Multiple sclerosis (MS) is an inflammatory, autoimmune disease that affects the central nervous system (CNS). One of the commonly used models…

Neurofilament Light Chains: A Reliable Biomarker of Disease Activity in MS

1Ayesha Ashfaq 1Sheikh Zayed Medical Complex, Lahore, Pakistan Background: With this study we aim to establish the importance of non radiological biomarkers of MS in establishing Prognostic value of disease activity in CIS. Monitoring disease activity in Relapsing remitting Multiple Sclerosis. Establish the value of quantification of neurofilament light chains in progressive multiple sclerosis in…